Landscape Capital Management L.L.C. bought a new stake in IO Biotech, Inc. (NASDAQ:IOBT - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 442,196 shares of the company's stock, valued at approximately $407,000. Landscape Capital Management L.L.C. owned approximately 0.67% of IO Biotech as of its most recent SEC filing.
Separately, Vontobel Holding Ltd. purchased a new position in IO Biotech during the fourth quarter valued at approximately $30,000. 54.76% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of research firms have issued reports on IOBT. HC Wainwright reiterated a "buy" rating and issued a $12.00 target price on shares of IO Biotech in a research report on Tuesday, April 1st. Piper Sandler upgraded IO Biotech to a "strong-buy" rating in a report on Wednesday, March 12th.
Check Out Our Latest Stock Analysis on IO Biotech
IO Biotech Price Performance
IOBT traded down $0.00 during midday trading on Friday, hitting $0.86. 28,778 shares of the company's stock traded hands, compared to its average volume of 273,813. The company has a market cap of $56.46 million, a PE ratio of -0.63 and a beta of 0.08. The stock's fifty day simple moving average is $0.96 and its 200-day simple moving average is $0.96. IO Biotech, Inc. has a one year low of $0.66 and a one year high of $1.79.
About IO Biotech
(
Free Report)
IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.
Read More
Before you consider IO Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IO Biotech wasn't on the list.
While IO Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
